## (11) EP 3 401 320 A1

(12)

## **EUROPEAN PATENT APPLICATION**

(43) Date of publication: 14.11.2018 Bulletin 2018/46

(21) Application number: 18179904.0

(22) Date of filing: 14.03.2014

(51) Int Cl.:

C07F 9/6512 (2006.01) A61K 31/675 (2006.01) A61K 31/522 (2006.01) A61P 31/12 (2006.01) A61P 31/22 (2006.01) C07F 9/6561 (2006.01) C07F 9/6558 (2006.01) A61K 31/662 (2006.01) A61K 31/513 (2006.01) A61P 31/18 (2006.01) A61P 35/00 (2006.01)

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 15.03.2013 US 201361793993 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: 14764430.6 / 2 970 346

(71) Applicant: The Regents of the University of California
Oakland, CA 94607-5200 (US)

(72) Inventors:

HOSTETLER, Karl Y.
 Del Mar, CA California 92014 (US)

BEADLE, James R.
 San Diego, CA California 92130 (US)

VALIAEVA, Nadejda
 San Diego, CA California 92130 (US)

(74) Representative: J A Kemp 14 South Square Gray's Inn London WC1R 5JJ (GB)

## Remarks:

This application was filed on 26-06-2018 as a divisional application to the application mentioned under INID code 62.

- (54) ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS FOR USE IN TREATING HUMAN PAPILLOMA VIRUS, CERVICAL INTRAEPITHELIAL NEOPLASIA, ANAL INTRAEPITHELIAL NEOPLASIA, OR VULVAR INTRAEPITHELIAL NEOPLASIA
- (57) The present disclosure relates, inter alia, to a compound of Formula (la):

$$\begin{array}{c|c} B_{\text{Nuc}(a)} & O & O \\ \hline & O & P \\ \hline & & O \\ \hline & & & \\ X^{\text{a}} & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\$$

or a pharmaceutically acceptable salt thereof for use in treating human papilloma virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia to a subject in need thereof wherein:  $B_{Nuc}(a)$  is selected from the group consisting of:

